Clinical Trial: A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587242) titled 'A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping' on May 08.

Brief Summary: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Muscular Dystrophies Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) Muscular Disorders, Atrophic Muscular Disease Musculo...